Sturge-Weber Syndrome Market Research Report - Forecast till 2027

Sturge-Weber Syndrome Market: Information by Type (Type 1, Type 2 and Type 3), Diagnosis & Treatment (Treatment [Medication, Laser Therapy and Surgical Procedures], Diagnosis Magnetic Resonance Imaging (MRI), Computed Tomography (CT) Scan, Electroencephalogram (EEG) and Skull Radiography), End User (Hospital & Clinics, Diagnostic Centers) - Forecast till 2027

ID: MRFR/HC/3661-CR | | Region: Global | 85 pages

Sturge Weber Syndrome Market Overview


The Sturge Weber Syndrome Market is evaluated to grow at a CAGR of 5.0%. With the support from major drivers such as the rising prevalence of glaucoma, epilepsy, the Sturge Weber Syndrome Market Value will rise to USD 2.27 Bn in the studied forecast period 2021-2028. Sturge Weber syndrome is a congenital disorder. It is characterized by eye complications, port-wine stain birthmark, and others.


As per the Sturge Weber Syndrome Market Analysis by MRFR, it is estimated that North America will lead the market. However, the Asia-Pacific region is projected to record the fastest growth in the upcoming years. According to World Health Organisation (WHO), approximately 30 million people across the European Union countries were having a rare disease. As a result, the growth of the Sturge Weber Syndrome Market is evaluated to simultaneously increase in the forecast period.


COVID-19 Analysis


The increase in the spread of COVID-19 disease led to huge havoc across the world. Due to this, the focus of the healthcare sector shifted to contain the spread. Furthermore, it also reduced the Sturge Weber Syndrome Market Growth significantly. However, with the rising emphasis and support by the government, it is anticipated the market will have considerable growth. Also, the steps taken by the key players will further enhance the market growth.


Market Dynamics


Market Drivers


Important factors such as increasing cases of rare diseases and rising awareness among people will drive the market growth. Also, the increasing technological advancements are estimated to enhance the Sturge Weber Syndrome Global Market Growth.


Restraints


Factors such as high costs for the treatment of sturge weber syndrome are evaluated to slow down the growth of the Sturge Weber Syndrome Market. Along with that, the side effects related caused by the drugs for the treatment are also estimated to restraint the market growth.


Opportunities


There are various opportunities such as increasing Sturge Weber Syndrome Global Market Trends with increasing funds by the support from governments and key players. These funds will be helpful for development and research to boost the Sturge Weber Syndrome Market Outlook.


Challenges


One of the major challenges for the Sturge Weber Syndrome Market is the disruption in the supply chain. Along with that, problems can occur in the development, and research is speculated to hinder the market growth.


Cumulative Analysis


According to Sturge Weber Syndrome Market Forecast, the market value is estimated to reach up to USD 230 Million. The Compound Annual Growth Rate (CAGR) is further evaluated to rise up to 5.5% by the end of the projected forecast period 2021-2028. Increasing awareness for the treatment of rare diseases will impact the market positively.


Value Chain Analysis


With the improvement in the Sturge Weber Syndrome Market Trends and technological advancements, the market will expand in the future. Also, the rising demand for better healthcare facilities and crucial strategies by key players are estimated to enhance the value chain of the market.


Global Sturge-Weber syndrome market Size, by End User, 2017 (USD Million)   Sturge-Weber syndrome market


Source: MRFR Analysis


Market Segmentations


The Sturge Weber Syndrome Market Size is divided into treatment and diagnosis, end-user, and type. On the basis of Type, the market is divided into Type 2, Type3, and Type 1.


On the basis of end-user, the Sturge Weber Syndrome Market is divided into Diagnostic Centres, Clinics and Hospitals, and Others. In the year 2017, the clinics and hospitals segment accounted for a market value of USD 1,257.72 Million. Therefore, the revenue of this section will further increase in the forthcoming years.


On the basis of Treatment, the Sturge Weber Syndrome Market is divided into Surgical Procedure, and Laser Therapy. The laser treatment is further divided into medication which is again divided into Antiglaucoma and Antiepileptic. Furthermore, Antiglaucoma is divided into carbonic Anhydrase Inhibitors, Beta Antagonist Eye Drops, and Latanoprost. 


The Diagnosis segment of the Sturge Weber Syndrome Global Market is divided into Skull Radiography, Magnetic resonance imaging (MRI), Electroencephalogram, and Computed Topography.


Regional Analysis


Geographically, the Sturge Weber Syndrome Market Size is divided into Asia-Pacific, North America, Africa, and the Middle East, and Europe. According to the Sturge Weber Syndrome Global Market Analysis by MRFR, North America will dominate the market in the upcoming years of the forecast period 2021-2028. The increasing research for the funds for treating rare diseases and technological development is the crucial driver.


Secondly, Europe is estimated to have the second-largest Sturge Weber Syndrome Market Share in the estimated forecast period. Several driving factors such as increasing expenditure for healthcare, support from the government are fuelling the market growth in this region.


However, the Asia-Pacific region is evaluated to have the fastest growth in the upcoming years. Due to the rising demand for early diagnosis and improvement in technology, the market will record immense growth. Also, countries such as India, China, Japan, etc. are contributing to the immense Sturge Weber Syndrome Global Market Growth. Also, the supportive funds and initiatives by the government will further boost the market growth in Asia-Pacific.


Asia-Pacific Sturge-Weber syndrome market Share, by Country, 2017 (%)  Sturge-Weber syndrome market


Source: MRFR Analysis


Competitive Landscape


The key players in the Sturge Weber Syndrome Market apply various market strategies to improve their business. They do mergers, partnerships, collaboration, new ventures, and product launches, acquisitions, etc. Some of the important key players in the Sturge Weber Syndrome Market are as follows.



  • Shire (Ireland)

  • ElectoCore LLC (US)

  • GW Pharmaceuticals, PLC (US)

  • Johnson and Johnson (US)

  • Pfizer Inc. (US)

  • Abbot (US)

  • Aleva Neurotherapeutics SA (Switzerland)

  • Hoffman-La Roche AG

  • Sanofi (France)

  • UCB SA (Belgium)


Recent Developments



  • Shire in 2017 announced its FDA approval for its product called MYDAYIS. This is used for treating patients from the age of 13 and above.

  • UCB SA in 2018 acquired a nasal spray from a company called Promixagen. This acquisition will help UCB SA to enhance its portfolio in epilepsy treatment.

  • Novartis AG in 2018 acquired a company called AveXis. This acquisition is done for widening the portfolio in the sector of neuroscience and gene therapy.


Report Overview


The overview of the Sturge Weber Syndrome Market Outlook is as follows.



  • Market Overview

  • COVID-19 Analysis

  • Dynamics of the Market

  • Value Chain Analysis

  • Market Segmentation

  • Regional Analysis

  • Competitive Analysis

  • Recent Development


Report Score and Segmentation


The report score is to provide significant information to support the Sturge Weber Syndrome Market Analysis. It highlights valuable information such as drivers, opportunities, challenges, etc. the information provided in this report is collected from secondary and primary sources.



  • Study Period- 2021-2028

  • Base Year-2021

  • Forecast Period- 2021-2028

  • Historical Period-2017-2020


Segmentation



  • By Type


Type I


Type II


Type III


 



  • By End-User


Clinics and Hospitals


Diagnostic Centres


Others



  • By Diagnosis and Treatment

  • Diagnosis

  • Electroencephalogram (EEG)

  • Skull Radiography

  • Computer Tomography (CT) Scan

  • Magnetic Resonance Imaging (MRI)

  • Treatment

  • Surgical Procedure

  • Laser Therapy

  • Medication

  • Antiglaucoma

  • Carbonic Anhydrase Inhibitors

  • Beta Antagonist Eye Drops

  • Latanoprost

  • Others

  • Antiepileptic


 



  • By Region


North America


Asia-Pacific


Africa and the Middle East


Europe



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 2,277.4 Million
  • 2027: Significant Value
  •   CAGR   5.3% (2015-2023)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Diagnosis & Treatment, End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Abbott (US), Pfizer Inc. (US), F. Hoffmann-La Roche AG (Switzerland), Novartis AG (Switzerland), UCB SA (Belgium), Sanofi (France), Shire (Ireland), Aleva Neurotherapeutics SA (Switzerland), GW Pharmaceuticals, PLC (US), ElectroCore LLC (US), and Johnson & Johnson (US)
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Increasing prevalence of epilepsy and glaucoma
  • Rising research and development
  • Growing focus on players towards Sturge-Weber syndrome


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :


    Sturge-weber syndrome market is projected to grow at a 5.3% CAGR between 2020-2027.

    The Americas is expected to dominate the sturge-weber syndrome market.

    Sturge-weber syndrome market is predicted to touch USD 2,277.4 million by 2023.

    Hospitals and clinics will dominate the sturge-weber syndrome market.

    Certain side effects may limit the sturge-weber syndrome market growth.

    1 Report Prologue

    2 Executive Summary

    3 Market Introduction

    3.1 Definition 19

    3.2 Scope Of The Study 19

    3.3 Assumptions & Limitations 19

    3.3.1 Assumptions 19

    3.3.2 Limitations 19

    3.4 Market Structure 19

    4 Research Methodology

    4.1 Research Process 21

    4.1 Primary Research 22

    4.2 Secondary Research 23

    4.3 Market Size Estimation 24

    4.4 Forecast Model 24

    5 Market Dynamics

    5.1 Introduction 26

    5.2 Drivers 27

    5.2.1 The Increasing Prevalence Of Epilepsy And Glaucoma 27

    5.2.2 Rising Research And Development Funding For Rare Diseases 27

    5.2.3 Increasing Focus On Players Towards Sturge-Weber Syndrome 27

    5.3 Restraints 28

    5.3.1 Side Effects Of Therapeutic Drugs 28

    5.4 Opportunities 28

    5.4.1 Rising Demand For Laser Therapy 28

    5.5 Macroeconomic Indicators 28

    6 Market Factor Analysis

    6.1 Supply Chain Analysis 30

    6.1.1 R&D 30

    6.1.2 Parts Manufacturing 30

    6.1.3 Distribution 30

    6.1.4 Marketing & Sales 30

    6.1.5 Post-Sales Monitoring 30

    6.2 Demand & Supply: Gap Analysis 31

    6.3 Pricing Analysis 31

    6.4 Investment Opportunities 31

    6.5 Porter’s Five Forces Model 32

    6.5.1 Bargaining Power Of Suppliers 33

    6.5.2 Bargaining Power Of Buyers 33

    6.5.3 Threat Of New Entrants 33

    6.5.4 Threat Of Substitutes 33

    6.5.5 Intensity Of Rivalry 33

    7 Sturge-Weber Syndrome Market, By Type

    7.1 Overview 35

    7.1.1 Type 1 35

    7.1.2 Type 2 35

    7.1.3 Type 3 35

    8 Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    8.1 Overview 39

    8.1.1 Treatment 39

    8.1.2 Diagnosis 39

    9 Sturge-Weber Syndrome Market, By End-User

    9.1 Overview 47

    9.1.1 Hospital & Clinics 47

    9.1.2 Diagnostic Centre 47

    10 Sturge-Weber Syndrome Market, By Region

    10.1 Introduction 49

    10.2 Americas 51

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.2.1 North America 54

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.2.1.1 U.S. 56

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.2.1.2 Canada 58

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.2.2 South America 60

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3 Europe 63

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3.1 Western Europe 66

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3.1.1 Germany 69

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3.1.2 France 71

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3.1.3 U.K 73

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3.1.4 Italy 75

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3.1.5 Spain 77

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3.1.6 Rest Of Western Europe 79

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.3.2 Eastern Europe 81

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.4 Asia Pacific 84

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.4.1 Japan 87

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.4.2 China 89

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.4.3 India 91

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.4.4 Australia 93

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.4.5 Republic Of Korea 95

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.4.6 Rest Of Asia Pacific 97

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.5 The Middle East And Africa 99

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.5.1 Middle East 102

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    10.5.2 Africa 104

    Sturge-Weber Syndrome Market, By Type

    Sturge-Weber Syndrome Market, By Diagnosis & Treatment

    Sturge-Weber Syndrome Market, By End-User

    11 Competitive Landscape

    11.1 Company Market Share Analysis 107

    11.1.1 Introduction 107

    11.2 Competitive Landscape 108

    11.2.1 Introduction 108

    11.3 Key Developments 109

    12 Company Profiles

    12.1 Abbott 111

    12.1.1 Company Overview 111

    12.1.2 Financial Overview 111

    12.1.3 Products Offerings 112

    12.1.4 Key Developments 112

    12.1.5 SWOT Analysis 112

    12.1.6 Key Strategy 112

    12.2 Pfizer Inc. 113

    12.2.1 Company Overview 113

    12.2.2 Financial Overview 113

    12.2.3 Products Offerings 114

    12.2.4 Key Developments 114

    12.2.5 SWOT Analysis 114

    12.2.6 Key Strategy 115

    12.3 F. Hoffmann-La Roche AG 116

    12.3.1 Company Overview 116

    12.3.2 Financial Overview 116

    12.3.3 Products Offerings 117

    12.3.4 Key Developments 117

    12.3.5 SWOT Analysis 117

    12.3.6 Key Strategy 117

    12.4 Novartis AG 118

    12.4.1 Company Overview 118

    12.4.2 Financial Overview 118

    12.4.3 Products Offerings 119

    12.4.4 Key Developments 119

    12.4.5 SWOT Analysis 119

    12.4.6 Key Strategy 119

    12.5 UCB S.A. 120

    12.5.1 Company Overview 120

    12.5.2 Financial Overview 120

    12.5.3 Products Offerings 121

    12.5.4 Key Developments 121

    12.5.5 SWOT Analysis 121

    12.5.6 Key Strategy 122

    12.6 Sanofi 123

    12.6.1 Company Overview 123

    12.6.2 Financial Overview 123

    12.6.3 Products Offerings 124

    12.6.4 Key Developments 124

    12.6.5 SWOT Analysis 124

    12.6.6 Key Strategy 124

    12.7 Shire 125

    12.7.1 Company Overview 125

    12.7.2 Financial Overview 125

    12.7.3 Products Offerings 126

    12.7.4 Key Developments 126

    12.7.5 SWOT Analysis 127

    12.7.6 Key Strategy 127

    12.8 Aleva Neurotherapeutics SA 128

    12.8.1 Company Overview 128

    12.8.2 Products Offering 128

    12.8.3 Key Developments 128

    12.8.4 SWOT Analysis 128

    12.8.5 Key Strategy 128

    12.9 GW Pharmaceuticals, Plc. 129

    12.9.1 Company Overview 129

    12.9.2 Financial Overview 129

    12.9.3 Products Offerings 130

    12.9.4 Key Developments 130

    12.9.5 SWOT Analysis 130

    12.9.6 Key Strategy 130

    12.10 ElectroCore LLC 131

    12.10.1 Company Overview 131

    12.10.2 Products Offerings 131

    12.10.3 Key Developments 131

    12.10.4 SWOT Analysis 131

    12.10.5 Key Strategy 131

    12.11 Johnson & Johnson 132

    12.11.1 Company Overview 132

    12.11.2 Financial Overview 132

    12.11.3 Products Offerings 133

    12.11.4 Key Developments 133

    12.11.5 SWOT Analysis 133

    12.11.6 Key Strategy 133

    13 Appendix

    13.1 Discussion Blue Print 135

    13.2 References 136

    14 List Of Tables

    TABLE 1 MARKET SYNOPSIS 17

    TABLE 1 PRIMARY INTERVIEWS 22

    TABLE 2 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 1, BY REGION 2020–2027 (USD MILLION) 36

    TABLE 3 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 2, BY REGION 2020–2027 (USD MILLION) 36

    TABLE 4 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TYPE 3, BY REGION 2020–2027 (USD MILLION) 37

    TABLE 5 GLOBAL STURGE-WEBER SYNDROME MARKET FOR TREATMENT, BY REGION 2020–2027 (USD MILLION) 40

    TABLE 6 GLOBAL STURGE-WEBER SYNDROME MARKET FOR DIAGNOSIS, BY REGION 2020–2027 (USD MILLION) 40

    TABLE 7 GLOBAL STURGE-WEBER SYNDROME MARKET FOR MEDICATION, BY REGION 2020–2027 (USD MILLION) 40

    TABLE 8 GLOBAL STURGE-WEBER SYNDROME MARKET FOR LASER THERAPY, BY REGION 2020–2027 (USD MILLION) 41

    TABLE 9 GLOBAL STURGE-WEBER SYNDROME MARKET FOR SURGICAL PROCEDURES, BY REGION 2020–2027 (USD MILLION) 41

    TABLE 10 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ANTIEPILEPTIC, BY REGION 2020–2027 (USD MILLION) 41

    TABLE 11 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ANTIGLAUCOMA, BY REGION 2020–2027 (USD MILLION) 42

    TABLE 12 GLOBAL STURGE-WEBER SYNDROME MARKET FOR LATANOPROST, BY REGION 2020–2027 (USD MILLION) 42

    TABLE 13 GLOBAL STURGE-WEBER SYNDROME MARKET FOR BETA-ANTAGONIST EYE DROPS, BY REGION 2020–2027 (USD MILLION) 42

    TABLE 14 GLOBAL STURGE-WEBER SYNDROME MARKET FOR CARBONIC ANHYDRASE INHIBITORS, BY REGION 2020–2027 (USD MILLION) 43

    TABLE 15 GLOBAL STURGE-WEBER SYNDROME MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION 2020–2027 (USD MILLION) 43

    TABLE 16 GLOBAL STURGE-WEBER SYNDROME MARKET FOR COMPUTED TOMOGRAPHY (CT) SCAN, BY REGION 2020–2027 (USD MILLION) 43

    TABLE 17 GLOBAL STURGE-WEBER SYNDROME MARKET FOR ELECTROENCEPHALOGRAM (EEG), BY REGION 2020–2027 (USD MILLION) 44

    TABLE 18 GLOBAL STURGE-WEBER SYNDROME MARKET FOR SKULL RADIOGRAPHY, BY REGION 2020–2027 (USD MILLION) 44

    TABLE 19 GLOBAL STURGE-WEBER SYNDROME MARKET FOR HOSPITAL & CLINICS, BY REGION 2020–2027 (USD MILLION) 46

    TABLE 20 GLOBAL STURGE-WEBER SYNDROME MARKET FOR DIAGNOSTIC CENTERS, BY REGION 2020–2027 (USD MILLION) 46

    TABLE 21 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020–2027 (USD MILLION) 49

    TABLE 22 AMERICAS: STURGE-WEBER SYNDROME MARKET, BY REGION, 2020–2027 (USD MILLION) 51

    TABLE 23 AMERICAS STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

    TABLE 24 AMERICAS STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 52

    TABLE 25 AMERICAS TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

    TABLE 26 AMERICAS MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 52

    TABLE 27 AMERICAS ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

    TABLE 28 AMERICAS DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 53

    TABLE 29 AMERICAS STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 53

    TABLE 30 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 54

    TABLE 31 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

    TABLE 32 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 54

    TABLE 33 NORTH AMERICA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 54

    TABLE 34 NORTH AMERICA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

    TABLE 35 NORTH AMERICA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

    TABLE 36 NORTH AMERICA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 55

    TABLE 37 NORTH AMERICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 56

    TABLE 38 U.S. STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

    TABLE 39 U.S. STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 56

    TABLE 40 U.S. TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 56

    TABLE 41 U.S. MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

    TABLE 42 U.S. ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

    TABLE 43 U.S. DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 57

    TABLE 44 U.S. STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 58

    TABLE 45 CANADA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

    TABLE 46 CANADA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 58

    TABLE 47 CANADA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 58

    TABLE 48 CANADA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

    TABLE 49 CANADA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

    TABLE 50 CANADA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 59

    TABLE 51 CANADA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 60

    TABLE 52 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

    TABLE 53 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 60

    TABLE 54 SOUTH AMERICA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 60

    TABLE 55 SOUTH AMERICA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

    TABLE 56 SOUTH AMERICA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

    TABLE 57 SOUTH AMERICA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 61

    TABLE 58 SOUTH AMERICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 62

    TABLE 59 EUROPE STURGE-WEBER SYNDROME MARKET, BY REGION, 2020–2027 (USD MILLION) 63

    TABLE 60 EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

    TABLE 61 EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 64

    TABLE 62 EUROPE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

    TABLE 63 EUROPE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 64

    TABLE 64 EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

    TABLE 65 EUROPE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 65

    TABLE 66 EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 65

    TABLE 67 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 66

    TABLE 68 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 66

    TABLE 69 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 66

    TABLE 70 WESTERN EUROPE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

    TABLE 71 WESTERN EUROPE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

    TABLE 72 WESTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 67

    TABLE 73 WESTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 68

    TABLE 74 WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 68

    TABLE 75 GERMANY STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

    TABLE 76 GERMANY STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 69

    TABLE 77 GERMANY TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

    TABLE 78 GERMANY MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 69

    TABLE 79 GERMANY ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

    TABLE 80 GERMANY DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 70

    TABLE 81 GERMANY STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 70

    TABLE 82 FRANCE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

    TABLE 83 FRANCE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 71

    TABLE 84 FRANCE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

    TABLE 85 FRANCE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 71

    TABLE 86 FRANCE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

    TABLE 87 FRANCE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 72

    TABLE 88 FRANCE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 72

    TABLE 89 U.K. STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

    TABLE 90 U.K. STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 73

    TABLE 91 U.K. TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

    TABLE 92 U.K. MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 73

    TABLE 93 U.K. ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

    TABLE 94 U.K. DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 74

    TABLE 95 U.K. STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 74

    TABLE 96 ITALY STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

    TABLE 97 ITALY STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 75

    TABLE 98 ITALY TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

    TABLE 99 ITALY MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 75

    TABLE 100 ITALY ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

    TABLE 101 ITALY DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 76

    TABLE 102 ITALY STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 76

    TABLE 103 SPAIN STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

    TABLE 104 SPAIN STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 77

    TABLE 105 SPAIN TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

    TABLE 106 SPAIN MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 77

    TABLE 107 SPAIN ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

    TABLE 108 SPAIN DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 78

    TABLE 109 SPAIN STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 78

    TABLE 110 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

    TABLE 111 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 79

    TABLE 112 REST OF WESTERN EUROPE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 79

    TABLE 113 REST OF WESTERN EUROPE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

    TABLE 114 REST OF WESTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

    TABLE 115 REST OF WESTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 80

    TABLE 116 REST OF WESTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 81

    TABLE 117 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

    TABLE 118 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 81

    TABLE 119 EASTERN EUROPE TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 81

    TABLE 120 EASTERN EUROPE MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

    TABLE 121 EASTERN EUROPE ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

    TABLE 122 EASTERN EUROPE DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 82

    TABLE 123 EASTERN EUROPE STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 83

    TABLE 124 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84

    TABLE 125 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

    TABLE 126 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 85

    TABLE 127 ASIA PACIFIC TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

    TABLE 128 ASIA PACIFIC MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 85

    TABLE 129 ASIA PACIFIC ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

    TABLE 130 ASIA PACIFIC DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 86

    TABLE 131 ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 86

    TABLE 132 JAPAN STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

    TABLE 133 JAPAN STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 87

    TABLE 134 JAPAN TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

    TABLE 135 JAPAN MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 87

    TABLE 136 JAPAN ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

    TABLE 137 JAPAN DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 88

    TABLE 138 JAPAN STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 88

    TABLE 139 CHINA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

    TABLE 140 CHINA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 89

    TABLE 141 CHINA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

    TABLE 142 CHINA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 89

    TABLE 143 CHINA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 90

    TABLE 144 CHINA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 90

    TABLE 145 CHINA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 90

    TABLE 146 INDIA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

    TABLE 147 INDIA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 91

    TABLE 148 INDIA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

    TABLE 149 INDIA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 91

    TABLE 150 INDIA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

    TABLE 151 INDIA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 92

    TABLE 152 INDIA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 92

    TABLE 153 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

    TABLE 154 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 93

    TABLE 155 AUSTRALIA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

    TABLE 156 AUSTRALIA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 93

    TABLE 157 AUSTRALIA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

    TABLE 158 AUSTRALIA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 94

    TABLE 159 AUSTRALIA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 94

    TABLE 160 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

    TABLE 161 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 95

    TABLE 162 REPUBLIC OF KOREA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

    TABLE 163 REPUBLIC OF KOREA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 95

    TABLE 164 REPUBLIC OF KOREA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 96

    TABLE 165 REPUBLIC OF KOREA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 96

    TABLE 166 REPUBLIC OF KOREA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 96

    TABLE 167 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

    TABLE 168 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 97

    TABLE 169 REST OF ASIA PACIFIC TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

    TABLE 170 REST OF ASIA PACIFIC MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 97

    TABLE 171 REST OF ASIA PACIFIC ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 98

    TABLE 172 REST OF ASIA PACIFIC DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 98

    TABLE 173 REST OF ASIA PACIFIC STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 98

    TABLE 174 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY REGION, 2020–2027 (USD MILLION) 99

    TABLE 175 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 99

    TABLE 176 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 100

    TABLE 177 MIDDLE EAST AND AFRICA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 100

    TABLE 178 MIDDLE EAST AND AFRICA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 100

    TABLE 179 MIDDLE EAST AND AFRICA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 101

    TABLE 180 MIDDLE EAST AND AFRICA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 101

    TABLE 181 MIDDLE EAST AND AFRICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 101

    TABLE 182 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

    TABLE 183 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 102

    TABLE 184 MIDDLE EAST TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

    TABLE 185 MIDDLE EAST MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 102

    TABLE 186 MIDDLE EAST ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 103

    TABLE 187 MIDDLE EAST DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 103

    TABLE 188 MIDDLE EAST STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 103

    TABLE 189 AFRICA STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

    TABLE 190 AFRICA STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020–2027 (USD MILLION) 104

    TABLE 191 AFRICA TREATMENT MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

    TABLE 192 AFRICA MEDICATION MARKET, BY TYPE, 2020–2027 (USD MILLION) 104

    TABLE 193 AFRICA ANTIGLAUCOMA MARKET, BY TYPE, 2020–2027 (USD MILLION) 105

    TABLE 194 AFRICA DIAGNOSIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 105

    TABLE 195 AFRICA STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020–2027 (USD MILLION) 105

    TABLE 196 GLOBAL STURGE-WEBER SYNDROME MARKET: KEY DEVELOPMENT 109

    15 List Of Figures

    FIGURE 1 GLOBAL STURGE-WEBER SYNDROME MARKET: MARKET STRUCTURE 19

    FIGURE 2 RESEARCH PROCESS OF MRFR 21

    FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 24

    FIGURE 4 MARKET DYNAMICS ANALYSIS OF GLOBAL STURGE-WEBER SYNDROME MARKET 26

    FIGURE 5 SUPPLY CHAIN: STURGE-WEBER SYNDROME MARKET 30

    FIGURE 6 PORTER'S FIVE FORCES ANALYSIS OF THE GLOBAL STURGE-WEBER SYNDROME MARKET 32

    FIGURE 7 GLOBAL STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020 (% SHARE) 35

    FIGURE 8 GLOBAL STURGE-WEBER SYNDROME MARKET, BY TYPE, 2020 & 2027 (USD MILLION) 36

    FIGURE 9 GLOBAL STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020 (% SHARE) 39

    FIGURE 10 GLOBAL STURGE-WEBER SYNDROME MARKET, BY DIAGNOSIS & TREATMENT, 2020 & 2027 (USD MILLION) 39

    FIGURE 11 GLOBAL STURGE-WEBER SYNDROME MARKET, BY END-USER, 2020 (% SHARE) 47

    FIGURE 12 GLOBAL STURGE-WEBER SYNDROME MARKET, BY APPLICATION, 2020 & 2027 (USD MILLION) 47

    FIGURE 13 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020 & 2027 (USD MILLION) 49

    FIGURE 14 GLOBAL STURGE-WEBER SYNDROME MARKET, BY REGION, 2020 (% SHARE) 50

    FIGURE 15 AMERICAS: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 51

    FIGURE 16 EUROPE: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 63

    FIGURE 17 ASIA PACIFIC: STURGE-WEBER SYNDROME MARKET SHARE, BY COUNTRY, 2020 (%) 84

    FIGURE 18 THE MIDDLE EAST AND AFRICA: STURGE-WEBER SYNDROME MARKET SHARE, BY REGION, 2020 (%) 99

    FIGURE 19 GLOBAL STURGE-WEBER SYNDROME MARKET, MARKET SHARE ANALYSIS 2020 (%) 107

    FIGURE 20 GLOBAL STURGE-WEBER SYNDROME MARKET: COMPETITIVE LANDSCAPE 2020 (%) 108



    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.

    Global Struge-Weber Syndrome Market: Competitive Landscape


    UCB S.A., Shire Plc, and Sanofi S.A. collectively accounted for more than 46% of the market share of the global Sturge-weber syndrome market in 2017. These companies continue to retain their strong global presence through collaborations, mergers & acquisitions, and product launches.


    In 2017, UCB S.A. was the leading market player. The company holds more one-fourth market of the global struge-weber syndrome market. Through the years, UCB S.A has established itself as a major brand with a robust product portfolio, and strategies for patient value. In the last few years, the company has adopted an organic strategy of acquisitions and partnerships with small and large companies. For instance, in 2018, UCB Pharma Ltd. announced the acquisition of midazolam nasal spray with Proximagen to expand its epilepsy portfolio.


    In 2017, Shire plc held the second position in terms of market share. The company develops drugs for rare diseases and aims to provide breakthrough therapies that enable people with altering conditions to live their lives to the fullest. It focuses on developing and distributing innovative products which differentiates it from other players around the globe. For instance, in July 2017, the company announced that it had gained FDA approvals for MYDAYIS, which is used for patients aged 13 and above for the attention deficit hyperactivity syndrome. This also allowed the company to market products in the U.S. and other FDA regulated markets. The company also has a huge product portfolio that helps it gain a competitive edge in the global market.


    Sanofi S. A. a prominent market participant mainly focuses on strategies of diversifying, discovering, developing, and distributing therapeutic solutions. It also focuses on collaborations to expand its portfolio. In this regard, in March 2018, the company announced the complete acquisition of Bloveratlv Inc. which helps in expanding its portfolio in the specialty care segment.


    There are several other players present in the market that are also actively implementing growth strategies and striving for a greater market share, some of them include Abbott Laboratories, Pfizer Inc., F. Hoffmann-La Roche AG, Novartis AG, Aleva Neurotherapeutics SA, GW Pharmaceuticals, plc, ElectroCore LLC, and Johnson & Johnson. These companies are continue to seek regulatory approval for newly developed products and focus on M&A to solidify their position in the market. New product development is a key focus area for players as the demand for more effective treatment continues to grow.